# Pancreatic Cancer Pancreatic ductal adenocarcinoma is one of the deadliest solid tumours. Its resistance to chemotherapy and near-universal resistance to immunotherapy are driven by two defining features. The first is KRAS-dependent oncogenic signalling, active in more than 90% of cases. The second is a dense desmoplastic stroma that excludes immune cells and shields tumour cells from cytotoxic therapy. Urolithin A has one of its most coherent and multi-layered preclinical evidence bases in pancreatic cancer. Most of the work comes from a focused research programme using both xenograft models and genetically engineered mouse models that closely resemble human pancreatic-cancer biology. The literature now reaches beyond basic mechanism studies into in vivo survival data, combination work, and immunotherapy-sensitisation research. There are still no clinical trials of Urolithin A in pancreatic-cancer patients. Everything reviewed here is preclinical. ### Why pancreatic cancer is a logical target for Urolithin A Two features of pancreatic-cancer biology align directly with Urolithin A's known mechanisms. #### KRAS-driven PI3K/AKT/mTOR signalling Most pancreatic ductal adenocarcinomas carry activating KRAS mutations, most commonly KRAS G12D. KRAS drives constitutive activation of PI3K/AKT/mTOR signalling, supporting tumour-cell proliferation, survival, and resistance to apoptosis. Urolithin A is one of the more consistently described natural inhibitors of this pathway. That makes pancreatic cancer a direct mechanistic fit. #### Immunologically cold tumour microenvironment Pancreatic tumours are characterised by dense fibrosis, high infiltration of suppressive myeloid and regulatory immune cells, and striking exclusion of cytotoxic T cells. This is one reason checkpoint inhibitors usually fail in pancreatic cancer. There are often too few functional intratumoural T cells present for checkpoint blockade to rescue. Urolithin A appears able to remodel this stromal and immune environment. ### PI3K/AKT/mTOR pathway inhibition The 2019 *Molecular Cancer Therapeutics* study established PI3K/AKT/mTOR suppression as the core pancreatic-cancer mechanism. Across BxPC-3, AsPC-1, Capan-2, and PANC-1 cells, Urolithin A produced: * dose-dependent reduction in phospho-AKT * dose-dependent reduction in phospho-p70S6K * reduced proliferation * lower migration and invasion * apoptosis with caspase activation and PARP cleavage The upstream interpretation was that Urolithin A interfered with KRAS-driven PI3K signalling rather than directly inhibiting KRAS itself. That is important in pancreatic cancer because direct KRAS targeting has historically been difficult, and even newer KRAS-targeted approaches still leave large gaps across mutation classes. #### Xenograft validation This pathway effect was confirmed in vivo. Subcutaneous xenograft models in immunodeficient mice showed significant reductions in tumour volume and tumour weight after Urolithin A treatment. Tumour tissue at necropsy also showed reduced AKT and mTOR phosphorylation. That makes the in vitro mechanism more credible. #### KRAS-driven transgenic model The work also moved beyond xenografts into a PKT transgenic model. These mice carry oncogenic KRAS G12D together with loss of TGF-β receptor signalling, which drives fast, aggressive pancreatic-cancer development with a stroma that resembles human disease. In this model, Urolithin A improved overall survival compared with vehicle control. That is a stronger finding than xenograft shrinkage alone because the tumour develops through relevant oncogenic drivers in an intact disease context. ### Gemcitabine combination — an important nuance The same research programme also tested Urolithin A with gemcitabine. The result was important and more nuanced than a simple “better together” story. Combined Urolithin A and gemcitabine did not produce a survival benefit beyond Urolithin A monotherapy in the PKT model. Urolithin A alone outperformed gemcitabine alone. In another context, the combination improved survival compared with gemcitabine monotherapy, but again not beyond Urolithin A alone. This does **not** suggest antagonism. No survival penalty was seen with the combination. What it suggests is that, in these models, Urolithin A already had strong enough activity that gemcitabine did not clearly add to it. Whether the same pattern would hold at clinically refined dose schedules, with higher tumour burden, or in human disease remains unknown. The most honest practical takeaway is this: * no evidence of antagonism has emerged * no clear additive survival advantage over Urolithin A alone has been shown either * the combination still needs better pharmacologic and translational study ### Tumour microenvironment remodelling The 2023 *Cancer Research Communications* study extended the pancreatic-cancer work into the stromal immune microenvironment. This is the most clinically interesting part of the pancreatic story because stromal and immune exclusion are the main reasons immunotherapy fails in this disease. The study used both the PKT genetically engineered model and a KPC syngeneic model, which is widely considered one of the best available preclinical models of human pancreatic cancer. #### Stromal fibrosis reduction Urolithin A significantly reduced stromal fibrosis in pancreatic tumour tissue, confirmed by histologic staining. That matters because fibrosis acts as both a physical and signalling barrier to immune infiltration. Reducing fibrosis may help open the tumour to immune-cell access. #### Immunosuppressive-cell depletion Flow-cytometry analysis showed coordinated reductions in: * M2-like tumour-associated macrophages * myeloid-derived suppressor cells * regulatory T cells These are three of the main cell populations that enforce immune suppression in pancreatic cancer. Their reduction suggests a genuine remodelling of the tumour microenvironment rather than just a tumour-cell-directed effect. #### Cytotoxic immune-cell infiltration At the same time, Urolithin A increased: * CD4-positive T-cell infiltration * CD8-positive T-cell infiltration * memory-like T-cell features * lower PD-1 expression on infiltrating T cells Taken together, these findings suggest conversion of an immunologically cold tumour into a more immune-permissive one. That is exactly the kind of shift checkpoint inhibitors require if they are to work at all. ### Anti-PD-1 combination — survival benefit The microenvironment findings led directly to anti-PD-1 combination testing. In the PKT model, mice were assigned to vehicle, anti-PD-1 alone, Urolithin A alone, or Urolithin A plus anti-PD-1. The results were striking. * anti-PD-1 alone produced no meaningful survival benefit over vehicle * Urolithin A alone improved survival over vehicle * Urolithin A plus anti-PD-1 improved overall survival compared with anti-PD-1 alone * the combination was associated with greater intratumoural CD4-positive Th1 infiltration * the combination was reported as well tolerated, with only minimal additional body-weight loss compared with Urolithin A alone This is one of the most important findings anywhere in the current Urolithin A literature. Checkpoint inhibitors usually do not work in pancreatic cancer. Showing that Urolithin A can convert a checkpoint-resistant pancreatic-cancer model into one with checkpoint responsiveness has direct translational importance, even though it remains preclinical. An NIH-funded programme was specifically created to extend this line of work and support eventual clinical-trial design. ### What the research programme has said publicly The investigators behind this work have framed the core finding clearly. Their view is that Urolithin A alters the immunologically cold pancreatic-cancer microenvironment and allows stronger accumulation of reactive T cells, creating meaningful synergy with immunomodulatory therapy. That interpretation matches both the published data and the NIH funding rationale. ### What remains unknown Several important limits still matter. * no clinical trials in pancreatic-cancer patients * no established pancreatic-cancer-specific dose or schedule * no evidence yet in metastatic human pancreatic cancer, which is where most real patients are treated * no data with current first-line regimens such as FOLFIRINOX or gemcitabine plus nab-paclitaxel * no proof yet that anti-PD-1 sensitisation in mouse models will translate to patients * no clear answer yet on whether anti-CTLA-4 combinations could outperform anti-PD-1 combinations Even the strongest mouse models still do not capture the full heterogeneity and treatment history of human pancreatic cancer. ### Bottom line Pancreatic cancer is one of the strongest and most coherent cancer-specific settings for Urolithin A. That conclusion rests on several overlapping strengths: * direct relevance to KRAS-driven PI3K/AKT/mTOR biology * repeated in vivo evidence * survival benefit in a transgenic pancreatic model * strong stromal and immune remodelling data * one of the most compelling checkpoint-inhibitor sensitisation signals in the current literature The evidence is still entirely preclinical. Even so, pancreatic cancer is one of the clearest places where Urolithin A looks biologically serious rather than merely interesting. ### References Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer\ Remodeling of stromal immune microenvironment by Urolithin A improves survival with immune checkpoint blockade in pancreatic cancer\ Combining immunotherapy with Urolithin A to improve pancreatic cancer survival\ NCI grant summary on combination therapy for pancreatic cancer\ Urolithin A research overview and oncology applications\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/pancreatic-cancer.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.